T0	Outcomes 24 41	erectile function
T1	Outcomes 46 76	health-related quality of life
T2	Outcomes 221 261	the effectiveness and cost-effectiveness
T3	Outcomes 277 332	on erectile function and health-related quality of life
T4	Outcomes 932 1005	outcome was erectile function (International Index of Erectile Function-5
T5	Outcomes 1033 1238	included male ED-specific quality of life (MED-QoL), quality-adjusted life years (QALYs) using the generic Euroqol measure (EQ-5D), endothelial function, cardiovascular risk, cholesterol and health service
T6	Outcomes 1279 1310	difference in erectile function
T7	Outcomes 1425 1439	improvement in
T8	Outcomes 1486 1492	0.04).
T9	Outcomes 1493 1553	Both 10-year cardiovascular risk and low-density lipoprotein
T10	Outcomes 1678 1709	change in endothelial function.
T11	Outcomes 1710 1744	The frequency of sexual encounters
T12	Outcomes 1748 1791	correlated with improved erectile function.
T13	Outcomes 1792 1841	The joint distribution of costs and QALY benefits
T14	Outcomes 1876 1908	simvastatin being cost-effective
T15	Outcomes 2170 2178	analysis
T16	Outcomes 2182 2196	costs and QALY